Murine Monoclonal Antibodies against HLA Structures

Summary Five samples of tonsil, 10 reactive lymph nodes and 65 consecutive cases of non-Hodgkin lymphoma (NHL) were evaluated in suspension phenotyping with the monoclonal antibodies aLeu-I, aLeu-2a, aLeu-3a, OKT1, OKT3, OKT4, OKT6, OKT8, W6/32, 26/114, DA-2, 2DI, J5, AN51 and OKT9 together with conventional surface marking by rosetting (E, Fcy, Fcts, C3b, C3d) Previous reports on phenotyping in non Hodgkin's lymphoma (NHL) indicate marked heterogeneity within tumours of similar appearance and histological class. Nevertheless such studies have shown broad correlation between histological class and phenotype (Jaffe et al., 1974;Gajl-Peczalska et al., 1975; Stein, 1976; Stathopoulos et al., 1977; Brouet, et al., 1977;Jaffe et al., 1977;Lukes et al., 1978; Stein et al., 1979;Habeshaw et al., 1979;Janossy et al., 1980;Aisenberg, 1981) A significant effect of these studies has been to focus attention on the cellular origin, differentiation and possible pathogenic role of the cell populations within the lesions. This applies particularly to the T cell populations accompanying B lymphocytic neoplasia of follicular and immunoblastic types (Habeshaw et al., 1979;Janossy et al., 1980), which until recently were evaluable only on the basis of E rosette formation, or reactivity with heteroantisera of pan T cell or limited T cell subset specificity (Evans et al., 1978

show abstract

“…W6/32 Monoclonal IgG2a antibody reactive with the 43K glycoprotein "core" chain of HLA A, B, (C) antigens (Trucco et al, 1979).…”

Section: Phenotypic Heterogeneity In Peripheral Tcellsmentioning

confidence: 99%

The cellular content of non Hodgkin lymphomas: A comprehensive analysis using monoclonal antibodies and other surface marker techniques

Habeshaw¹,

Bailey²,

Stansfeld³

et al. 1983

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…1), or the allotypic site (MT2, E3. 15/4) of the HLA-DR molecule has been described previously (21,24). S1.34/28 is a monomorphic monoclonal antibody directed against the common part of the HLA-A, -B, and -C molecules (21,25).…”

Section: Methodsmentioning

confidence: 99%

“…MTI clone has been derived from one of the seven hypoxanthine-azaserine-resistant cell colonies detected 2 wk after fusion between the 6-thioguanine-resistant mutant (6TM) ofthe Jurkat human T-lymphoma cell line and phytohaemagglutinin-stimulated peripheral blood lymphocytes from a healthy female volunteer in the presence of polyethylene glycol 1500 (21). MTl clone secretes in culture medium a factor (CIL) able to inhibit haematopoietic progenitor cell proliferation (20).…”

Section: Methodsmentioning

confidence: 99%

“…15/4) of the HLA-DR molecule has been described previously (21,24). S1.34/28 is a monomorphic monoclonal antibody directed against the common part of the HLA-A, -B, and -C molecules (21,25). All of the monoclonal antibodies were affinity-purified on a Protein A column (26) and resuspended in phosphate-buffered saline (PBS) to a concentration of 2 mg/ml.…”

Section: Methodsmentioning

confidence: 99%

“…PBL cells from normal donors were HLA-A, -B, and -C serotyped with highly selective reagents in the standard National Institutes of Health two-stage complementdependent lymphocytotoxicity technique at room temperature. HLA-DR determinants were typed on B cell-enriched suspensions using the same method adapted for B cells (21).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Inhibitory effect of a human T cell hybrid factor on both cell growth and mixed lymphocyte reactivity. Correlation with class II molecule expression.

Trucco¹,

Shaw²,

Korngold³

1985

J. Clin. Invest.

View full text Add to dashboard Cite

We recently reported the biological activity and some of the biochemical characteristics of a factor produced by a human T cell hybrid clone able to block hematopoietic progenitor cell proliferation. This 85-kD protein factor, which we have termed colony-inhibiting lymphokine (CIL), has growth regulatory activity on bone marrow precursors bearing Ia (class II) antigens of either granulocytic-monocytic (CFU-GM) or erythroid lineage (BFU-E and CFU-E). Experiments aimed to investigate the specificity of the inhibitory effect on hematopoietic progenitor cell growth suggested that the expression of HLA-DR surface antigens was required on the target cells. We describe in this communication how DR' cell lines ceased dividing after a few days of culture in the presence of CIL, whereas DR-cell lines were completely unaffected. The increased DR expression on the ML3 cell surface, mediated by the activity of the gamma interferon (IFNy), increases the sensitivity to the growth inhibition factor of the ML3 cell line. To verify the hypothesis that the DR antigens might serve as receptors for the factor, enabling it also to interfere in the immune response, we tested CIL in a mixed lymphocyte reaction (MLR), one of the best known in vitro Ia antigen-dependent T cell-mediated immune responses. CIL is able to block major histocompatibility comnplex-allogeneic MLR both in human and mouse systems. The data indicate that CIL recognizes a nonpolymorphic structure (presumably on all Ia molecules) presented by stimulator cells of either species, and thereby interferes with specific interactions between stimulator and responder cells. Blocking of the alloantigen stimulation stage is also indicated, since CIL is effective only if added to the culture medium during the first 48 h of the MLR. Finally, mouse monoclonal anti-DR antibodies are able to sharply reduce CIL activity on sensitive DR' cell lines. CIL may act physiologically as a multifunctional mediator in a complex network that links regulation of bone marrow differentiation and the generation of immune responses.

show abstract

Binding of one monoclonal antibody to human Ia molecules can be enhanced by a second monoclonal antibody

Tosi

Tanigaki

Sorrentino³

et al. 1981

Eur J Immunol

View full text Add to dashboard Cite

A monoclonal anti-human Ia antibody, PTF 29, was tested for its ability to bind purified, 125I-labeled human Ia preparations. It was found that the binding level increases considerably in the presence of a second monoclonal antibody. Experimental conditions were selected under which only the binding of PTF 29 and not the binding of the second antibody could be determined. Under these conditions, it was found that "helped" PTF 29 binding has higher affinity and is exerted on a molecular subset different from that bound by PTF 29 alone. This phenomenon, while not easily accommodated in the present conceptual framework of the human Ia system, appears in itself interesting and may have more general implications.

show abstract

Murine Monoclonal Antibodies against HLA Structures

Cited by 92 publications

References 28 publications

The cellular content of non Hodgkin lymphomas: A comprehensive analysis using monoclonal antibodies and other surface marker techniques

The cellular content of non Hodgkin lymphomas: A comprehensive analysis using monoclonal antibodies and other surface marker techniques

Inhibitory effect of a human T cell hybrid factor on both cell growth and mixed lymphocyte reactivity. Correlation with class II molecule expression.

Binding of one monoclonal antibody to human Ia molecules can be enhanced by a second monoclonal antibody

Contact Info

Product

Resources

About